Zacks Research Issues Pessimistic Outlook for TEVA Earnings

Key Points

• Zacks Research has decreased their Q3 2025 EPS estimate for Teva Pharmaceuticals from $0.69 to $0.66, with a full-year earnings consensus of $2.50 per share.
• Several research firms have recently adjusted their price targets for Teva, with UBS lowering its target to $23.00, while JPMorgan upgraded its rating and set a target of $23.00.
• Teva reported a Q2 2025 EPS of $0.66, slightly exceeding analysts' expectations, but the company's revenue fell short of the consensus estimate, coming in at $4.18 billion.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a note issued to investors on Thursday, September 4th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.66 per share for the quarter, down from their prior forecast of $0.69. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q1 2026 earnings at $0.51 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.75 EPS and Q4 2026 earnings at $0.71 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's quarterly revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS.

A number of other research analysts have also recently commented on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, UBS Group decreased their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA traded up $0.39 during trading hours on Monday, reaching $19.69. The company's stock had a trading volume of 12,962,752 shares, compared to its average volume of 9,877,037. The firm's 50-day moving average price is $17.15 and its 200-day moving average price is $16.43. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market capitalization of $22.58 billion, a price-to-earnings ratio of -123.06, a PEG ratio of 1.12 and a beta of 0.72.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its position in Teva Pharmaceutical Industries by 31.9% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company's stock valued at $645,148,000 after acquiring an additional 9,303,978 shares during the last quarter. Phoenix Financial Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 31.7% in the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company's stock worth $632,882,000 after buying an additional 9,094,372 shares during the period. Soundwatch Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $143,533,000. Finally, Duquesne Family Office LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 65.4% in the 1st quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock worth $228,702,000 after buying an additional 5,882,350 shares during the period. Institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.